A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitum

Trial Details

NCT ID
NCT07699328
Phase
PHASE1 / PHASE2
Sponsor
Voronoi, Inc
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • VRN110755
Locations (sample)
  • Bedford Park, South Australia, Australia|-35.02204,138.56815
  • Clayton, Victoria, Australia|-37.91667,145.11667
  • Toronto, Ontario, Canada|43.70643,-79.39864
  • Marseille, Bouches-du-Rhône, France|43.29695,5.38107
  • Dijon, Côte-d'Or, France|47.31344,5.01391

Key Eligibility Criteria

  • Adults aged 18 years or older (19 years or older in the Republic of Korea).
  • Able to understand, sign, and provide written informed consent.
  • Histologically or cytologically confirmed advanced, metastatic, or recurrent predominantly nonsquamous non-small cell lung cancer (NSCLC) with a do…
  • At least one measurable extracranial lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →